Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# Riverstone Bio

River Stone Biotech combines synthetic biology using microbes with synthetic chemistry reactions to find new, fast, cost-effective processes and pathways to manufacture active pharmaceutical ingredients such as prostaglandins, buprenorphine, naloxone, naltrexone and other molecules.

## Sitemaps

- [XML Sitemap](https://riverstonebio.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Dec. 2025 - New US patent further strengthens River Stone IP](https://riverstonebio.com/hello-world-2-4/) - River Stone Biotech have announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection on its unique approach to bioconversion across a range of products.
- [Nov. 2021 - River Stone Biotech Inc. Announces $6.8M Series B Financing](https://riverstonebio.com/hello-world-2-4-3/) - Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects To Treat Opiate Use Disorder and Opiate Overdose. – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of
- [Apr. 2022 - River Stone Biotech Inc. participates in DCAT 2022](https://riverstonebio.com/hello-world-2-3/) - Cambridge, April 28, 2022. River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone. The novel patent-protected technology employed
- [Jul. 2022 - River Stone Biotech Inc. Announces Issuance of U.S. Patent](https://riverstonebio.com/hello-world-2-2/) - River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the issuance of a U.S. Patent covering a unique production technology for the preparation of Buprenorphine. The process is higher efficiency and uses more environmentally-friendly reagents than conventional
- [Dec. 2023 - Advancing to global commercial launch](https://riverstonebio.com/hello-world-2/) - Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering, today announced the issuance of a U.S. Patent covering a key family of enzymes enabling preparation of precursors to high value compounds such as buprenorphine, naloxone, naltrexone, and nalmefene. These enzymes are key to enabling a
- [Oct. 2025 - River Stone to attend CPHI 2025](https://riverstonebio.com/hello-world-2-4-2/) - River Stone will be attending CPHI in Frankfurt next week. RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes. In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around

## Pages

- [Home](https://riverstonebio.com/) - Prostaglandins reactions Opioid reactions Make prostaglandins Make opioids API manufacturer API suppliers Enzymatic conversion Synthetic biology company Synthetic biology APIs Synthesise prostaglandins Synthesise APIs Synthesise opioid Buprenorphine supplier Naloxone supplier Naltrexone supplier Opioid fermentation Prostaglandin fermentation
- [TECHNOLOGY](https://riverstonebio.com/technology/) - “We simplify complex, expensive and environmentally challenging supply chains for small molecule APIs using the power of synthetic biology in combination with synthetic chemistry” Esben Halkjær Hansen, SVP R&D A Superior R&D Platform for Future Green Chemistry An enzyme is a protein that can catalyze a chemical reaction. The River Stone technology uses enzymes to
- [ABOUT](https://riverstonebio.com/about/) - “We simplify complex, expensive and environmentally challenging supply chains for small molecule APIs using the power of synthetic biology in combination with synthetic chemistry” Esben Halkjær Hansen, SVP R&D Who We Are At River Stone Biotech, we combine cutting-edge synthetic biology with proven chemical processing to set new standards in molecule manufacturing. Our proprietary platform
- [NEWS](https://riverstonebio.com/news/) - “Our result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.” Tim Bowser, CTO Dec. 2025 – New US patent River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 – New US Nov. 2025 –
- [TEAM](https://riverstonebio.com/team/) - Our highly experienced management team has taken multiple projects from concept through method development and into commercial-scale production. BOARD OF DIRECTORS Paul Goldenheim CEO Paul is trained as a pulmonary physician and has a long history in pharmaceutical research, development and management. He has held roles as CSO of Purdue Pharma, President of TransForm Pharmaceuticals
- [til test](https://riverstonebio.com/til-test/) - Nov. 2021 – $6.8M Series B Financing River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Adv Apr. 2022 – Participation DCAT 2022 River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business
- [CONTACT](https://riverstonebio.com/contact/) - PARTNERS & INVESTORS River Stone Biotech is dedicated to being a global leader in providing APIs for formulations across a range of therapeutic applications. For further information on investment opportunities, contact info@rstbio.com. CONTACT US FOR QUESTIONS & REQUESTS Your name Your email Subject Your message (optional) COSTUMERS Do you require assistance with product specifications, safety data
- [PRODUCTS](https://riverstonebio.com/products/) - Prostaglandins Sustainable, scalable, and cost-effective manufacturing Prostaglandins are powerful lipid-based molecules used as active pharmaceutical ingredients (APIs) in a range of therapies, including reproductive health, glaucoma and cardiovascular treatment. Our proprietary microbial production platform enables sustainable, scalable, and cost-effective manufacturing of high-purity prostaglandins, offering a reliable, easily scalable, and cost-competitive alternative to traditional chemical synthesis.
- [Other products](https://riverstonebio.com/other-products/) - Other Nal Products Products (bup nal) River Stone Biotech has leveraged the power of synthetic biology to simplify the production of alkaloid molecules, initially: Buprenorphine, Naloxone and Naltrexone. Whereas current industry standards utilize a complex chemistry process to generate these products, River Stone Biotech has discovered a synthetic pathway that uses a novel intermediate to
- [Naltrexone](https://riverstonebio.com/naltrexone/) - Products Naltrexone Naltrexone is a medication used in the treatment of alcohol use disorder and opioid use disorder. It is also used in combination with Bupropion as a therapeutic for obesity. River Stone Biotech produces Naltrexone hydrochloride in accord with the USP and EP Pharmacopoeia.
- [Naloxone](https://riverstonebio.com/naloxone/) - Products Naloxone Naloxone is an opioid antagonist and a life-saving medication that rapidly reverses opioid overdose – the leading cause of accidental deaths in the US. It may also be combined with Buprenorphine as a combination therapy for treating OUD. River Stone Biotech produces Naloxone Hydrochloride dihydrate in accord with the USP and EP Pharmacopoeia.
- [Buprenorphine](https://riverstonebio.com/buprenorphine/) - Products (Buprenorphine and the Nal Family) Buprenorphine Buprenorphine is a partial opioid agonist used as a core medication in the treatment of opioid use disorder (OUD). By reducing cravings and withdrawal symptoms while having a ceiling effect on respiratory depression, it supports safer, evidence-based maintenance therapy. Buprenorphine is also widely used in combination therapy with
- [Prostaglandins](https://riverstonebio.com/prostaglandins/)
- [RIVERSTONE BIO](https://riverstonebio.com/riverstone-bio/) - I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

## Portfolio

- [Nov. 2025 - Production of nororipavine](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-4-3/) - Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource Technology researchers of University of Melbourne and River Stone it is shown that optimized insect-derived N-demethylases of cytochrome P450 origin can efficiently convert the natural opioid oripavine to the much sought after chemical intermediate
- [Jul. 2024 - Glycosylation of aloesone](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn/) - Enzymatic glycosylation of aloesone performed by plant UDP-dependent glycosyltransferases . In a paper published in Glycobiology, researchers of the Danish Technical University (DTU) and River Stone demonstrates that a high number of natural UGTs (UDP-glucose dependent glycosyltransferases) are able to glycosylate the plant molecule aloesone. Aloesone and its derivatives are highly used in cosmetics, and
- [Nov. 2021 - $6.8M Series B Financing](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-2-2/) - River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects To Treat Opiate Use Disorder and Opiate Overdose. – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract
- [Apr. 2022 - Participation DCAT 2022](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-2-2-2/) - River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone.
- [Mar. 2025 - Enzyme Discovery and In Vivo Assessment](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-4-2/) - Plant-Derived UDP-Glycosyltransferases for Glycosylation-Mediated Detoxification of Deoxynivalenol: Enzyme Discovery, Characterization, and In Vivo Resistance Assessment . March 2025, Copenhagen - In a paper published in Toxins, DTU (Danish Technical University) and River Stone researchers used River Stone’s 380-member large UGT (UDP-glucose dependent glycosyltransferases) library (Gly-it.com) to identify 8 novel UGTs that could efficiently glycosylate the
- [Oct. 2025 - Attending CPHI 2025](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-2/) - River Stone will be attending CPHI in Frankfurt next week - october 2025 . RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes. In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance
- [Dec. 2025 - New US patent](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-4/) - River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 - New US patent further strengthens River Stone IP . This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection
- [Jul. 2022 - Issuance of U.S. Patent](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-2-3/) - River Stone Biotech Inc. Announces Issuance of U.S. Patent . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the issuance of a U.S. Patent covering a unique production technology for the preparation of Buprenorphine. The process
- [Dec. 2023 - Global commercial launch](https://riverstonebio.com/portfolio-item/bcjncgjknbcjkn-2-4/) - Advancing to global commercial launch . Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering, today announced the issuance of a U.S. Patent covering a key family of enzymes enabling preparation of precursors to high value compounds such as buprenorphine, naloxone, naltrexone, and nalmefene. These

## Categories

- [Uncategorized](https://riverstonebio.com/category/uncategorized/)

## Portfolio Categories

- [1](https://riverstonebio.com/portfolio-category/1/)
- [2](https://riverstonebio.com/portfolio-category/2/)
- [3](https://riverstonebio.com/portfolio-category/3/)
- [o](https://riverstonebio.com/portfolio-category/o/)